SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis First Subcutaneous Anti-TNF to Launch ...

SIMPONI is available either through the SmartJect® autoinjector/prefilled pen or a prefilled syringe as a subcutaneously administered injection. For more information about SIMPONI in the United States ...

SIMPONI (Golimumab) 50mg/0.5mL solution for SC inj from Centocor Ortho Biotech The FDA has approved Simponi (golimumab, from Centocor Ortho Biotech), a human monoclonal antibody, anti-tumor necrosis ...

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of ...

Issues with the device end a drug/device combination are behind this week's J&J product recall. The healthcare giant is retrieving two lots of prefilled Simponi SmartJect autoinjectors because they ...

rheumatoid arthritis and ankylosing spondylitis in adults psoriatic arthritis in adults and children ages 2 years and older polyarticular juvenile idiopathic arthritis in children ages 2 years and ...

If you have a certain kind of autoimmune condition, your doctor might suggest Simponi or Simponi Aria as a treatment option for you. The active ingredient in Simponi and Simponi Aria is golimumab. An ...

UK patients with psoriatic arthritis are on the brink of gaining access to an additional treatment option on the National Health Service in England and Wales after cost regulator's waved through Merck ...

Janssen Biotech announced the submission of a Biologics License Application (BLA) to the FDA requesting approval of an investigational intravenous formulation of Simponi (golimumab) for the treatment ...

HORSHAM, Pa., Sept. 27 Centocor Ortho Biotech Inc. announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to ...

SIMPONI is approved in 70 countries for rheumatologic indications, including the European Union (EU), where SIMPONI received European Commission approval in October 2009 for the treatment of ...

European regulators have given clearance to Johnson & Johnson/Schering-Plough’s Simponi for the treatment of three rheumatic conditions: rheumatoid arthritis; psoriatic arthritis; and ankylosing ...